Seaport Therapeutics, Inc.

Seaport Therapeutics is a clinical-stage therapeutics company dedicated to inventing and developing new medicines for patients suffering from depression, anxiety, and other debilitating neuropsychiatric disorders. Headquartered in Boston, Massachusetts, the company's mission is to transform the treatment landscape by identifying clinically validated mechanisms and overcoming historical limitations such as high first-pass metabolism, low bioavailability, and adverse side effects through its proprietary technology.

The core of Seaport Therapeutics' approach is its proprietary Glyph™ platform, a lymphatic-targeting prodrug technology. This platform is designed to bypass first-pass liver metabolism, thereby enhancing a drug's oral bioavailability, reducing side effects, and creating new composition-of-matter intellectual property. The company's pipeline includes GlyphAllo™ (SPT-300), an oral prodrug of allopregnanolone in a global Phase 2b trial for Major Depressive Disorder (MDD); GlyphAgo™ (SPT-320), a novel prodrug of agomelatine planned for Phase 2a/2b trials for Generalized Anxiety Disorder (GAD); and Glyph2BLSD™ (SPT-348), a non-hallucinogenic prodrug in preclinical development for depressive disorders and headache indications. Seaport also has GlyphCele, an oral prodrug of celecoxib, in development with ARPA-H funding.

Seaport Therapeutics recently completed an upsized initial public offering (IPO), with its common stock commencing trading on the Nasdaq Global Select Market under the ticker symbol "SPTX" on May 1, 2026, raising approximately $254.9 million in gross proceeds. The company is led by Founder, CEO, and Board Member Daphne Zohar, with Steven M. Paul, M.D., serving as Founder and Chair of the Board of Directors. The leadership team brings extensive experience in neuropsychiatry drug development, including key roles in the success of Karuna Therapeutics.